8 research outputs found
Le médecin roumain Victor Babes (28/07/1854-19/10/1926) (sa contribution dans le domaine de la rage et de la babesiose)
A l'aube du vingtième siècle, en Roumanie, la personnalité de Victor Babes (1854 1926) occupe le devant de la scène médicale. La présente évocation suit la vie de Victor Babes, étudie son parcours en tant que médecin et nous fait prendre connaissance de ses champs d'intérêt scientifique. Une attention particulière est portée sur ses travaux dans le domaine de la rage et celui de la babésiose. Il a débuté la vaccination antirabique en Roumanie et il a proposé la méthode roumaine de traitement de la rage. Il a découvert, dans le système nerveux, les corps Babes Negri , spécifiques pour la rage. Il a décrit le micro-organisme responsable de l'hémoglobinurie du boeuf, ultérieurement appelé Babésia. Son oeuvre tient une place importante dans l'histoire de la médecine roumaine et internationale.ROUEN-BU Médecine-Pharmacie (765402102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Le médecin roumain Victor Babes (28/07/1854-19/10/1926) (sa contribution dans le domaine de la rage et de la babesiose)
A l'aube du vingtième siècle, en Roumanie, la personnalité de Victor Babes (1854 1926) occupe le devant de la scène médicale. La présente évocation suit la vie de Victor Babes, étudie son parcours en tant que médecin et nous fait prendre connaissance de ses champs d'intérêt scientifique. Une attention particulière est portée sur ses travaux dans le domaine de la rage et celui de la babésiose. Il a débuté la vaccination antirabique en Roumanie et il a proposé la méthode roumaine de traitement de la rage. Il a découvert, dans le système nerveux, les corps Babes Negri , spécifiques pour la rage. Il a décrit le micro-organisme responsable de l'hémoglobinurie du boeuf, ultérieurement appelé Babésia. Son oeuvre tient une place importante dans l'histoire de la médecine roumaine et internationale.ROUEN-BU Médecine-Pharmacie (765402102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Expertise of French Laboratories in Detection, Genotyping, and Quantification of Hepatitis C Virus RNA in Serum
Before initiating new large-scale therapeutic trials for hepatitis C virus (HCV)-infected patients, the French Health Authorities for HCV research decided to organize an evaluation of the expertise of laboratories that could be engaged to undertake molecular biology assays in such trials; 21 experienced laboratories participated in this national evaluation of laboratory expertise, which was performed in two successive rounds. The first round evaluated the laboratories for their abilities to detect HCV RNA in serum, determine genotypes, and quantify HCV RNA loads. The results observed by qualitative assays for HCV RNA detection were 100% sensitivity and 100% specificity for all laboratories. The genotyping results were 100% concordant for 9 laboratories and greater than 90% for 10 laboratories. By contrast, large coefficients of variation were observed for quantitative determination of HCV RNA loads, leading to a second round with standardized quantitative assays only. The dispersion of the results was larger by the AMPLICOR HCV Monitor assay than by the branched-DNA assay (mean coefficients of variation, 57.4 and 16.9%, respectively). In the majority of cases, discrepancies between the results of the two tests were found for samples with high viral loads. These results indicate the usefulness of validating, by controlling for expertise, both the reliabilities of laboratories involved in multicenter work and the standardized assays chosen for use in the evaluation of the biological impacts of new therapies
Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay
International audienceThe aim of this study was to determine whether multicentre quality controls for the detectability of viral genomes could contribute to the improvement of diagnostic performance in the participating laboratories. The study was carried out during two successive rounds, during which 18 laboratories specialized in nucleic acid testing analyzed, through a polymerase chain reaction (PCR) assay, a common panel of GB virus C (GBV-C)/hepatitis G virus (HGV) RNA-positive and -negative samples. During the first round, the laboratories used either an 'in-house' PCR procedure or a partly standardized commercial test. After decoding the results of the first round, the procedures of the participating laboratories were compared in order to establish a consensus procedure deduced from those of the laboratories which provided the best results. During the second round, each participating laboratory could use the resulting consensus procedure, or its own procedure, or both. The results of this quality control study indicated that, whatever method used, even specialized and trained laboratories may give false-negative or false-positive results. The commercial assay did not guarantee a systematic high quality level of results. The striking heterogeneity of results observed among laboratories using the same commercial assay confirm that molecular biology methods need skilled technicians. The results of this quality control study suggest that full standardization of viral genome detection, including all steps of the procedure, is necessary and that the laboratories performing PCR should participate in repeated quality control studies, whatever technique is being used
GEMHEP multicenter quality control study of PCR detection of GB virus C/hepatitis G virus RNA in serum
International audiencePCR is, to date, the only available tool for the detection of GB virus C (GBV-C) and hepatitis G virus (HGV) RNAs. Twenty-two French laboratories participated in a quality control study to assess the sensitivity and specificity of their procedures. The panel included 13 positive controls and 7 negative controls. The laboratories used either in-house PCR techniques adapted from the literature or partly standardized commercial tests. Three laboratories performed faultlessly with the entire panel. Most laboratories had excellent specificity (100% in 20 of 22 laboratories). Sensitivity was acceptable (85 to 100%) in 15 centers and insufficient (38 to 77%) in 7. As with nonstandardized in-house PCR, the commercial assays gave discrepant performances in different laboratories. These results suggest that laboratories willing to use PCR for detection of GBV-C/HGV RNA for research or diagnostic purposes should participate in multicenter quality control trials